![]() |
|
||||||||||||||||||||||
Low or non-sedating antihistamines: |
||||||||||||||||||||||
cetirizine (Zyrtec):
|
||||||||||||||||||||||
|
Metabolite of hydroxyzine. Usual dose: 5-10 mg orally
once daily. Children >/= 6 years and Adults: Chronic urticaria, perennial or seasonal allergic rhinitis: 5-10 mg once daily, depending upon symptom severity Elderly Initial: 5 mg once daily; may increase to 10 mg/day. Note: Manufacturer recommends 5 mg/day in patients >/= 77 years of age. Dosage adjustment in renal/hepatic impairment: Children <6 years: Cetirizine use not recommended Children 6-11 years: <2.5 mg once daily Children >/= 12 and Adults: Clcr 11-31 mL/minute, hemodialysis, or hepatic impairment: Administer 5 mg once daily Clcr<11 mL/minute, not on dialysis: Cetirizine use not recommended. Supplied: Syrup, as hydrochloride: 5 mg/5 mL (120 mL, 480 mL) [banana-grape flavor] Tablet, as hydrochloride: 5 mg, 10 mg Tablet, chewable, as hydrochloride: 5 mg, 10 mg [grape flavor] |
||||||||||||||||||||||
desloratadine (Clarinex)
|
||||||||||||||||||||||
|
Adults: Allergic rhinitis, seasonal/perennial: 5 mg po qd. Chronic idiopathic urticaria: 5 mg po qd. In patients with liver or renal impairment, a starting dose of one 5 mg tablet every other day is recommended based on pharmacokinetic data. Mechanism of Action Desloratadine, a major metabolite of loratadine, is a long-acting tricyclic antihistamine with selective peripheral histamine H1 receptor antagonistic activity and additional anti-inflammatory properties. Dosing: Oral: Children: 6-11 months: 1 mg once daily 12 months to 5 years: 1.25 mg once daily 6-11 years: 2.5 mg once daily Children >/= 12 years and Adults: 5 mg once daily Supplied Syrup (Clarinex®): 0.5 mg/mL (480 mL) [bubble gum flavor] Tablet (Clarinex®): 5 mg Tablet, orally-disintegrating (Clarinex® RediTabs®): 5 mg [contains phenylalanine 1.75 mg/tablet] |
||||||||||||||||||||||
fexofenadine (Allegra):
|
||||||||||||||||||||||
|
Adult (usual) Chronic idiopathic urticaria: 60 mg
orally twice daily. Seasonal allergic rhinitis: 60 mg orally twice daily or 180 mg once daily. A dose of 60 mg once daily is recommended as the starting dose in patients with decreased renal function Mechanism of Action Fexofenadine is an active metabolite of terfenadine and like terfenadine it competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels and respiratory tract; it appears that fexofenadine does not cross the blood brain barrier to any appreciable degree, resulting in a reduced potential for sedation Dosage - Oral: Children 6-11 years: 30 mg twice daily Children >/= 12 years and Adults: Seasonal allergic rhinitis: 60 mg twice daily or 180 mg once daily Chronic idiopathic urticaria: 60 mg twice daily Supplied Tablet, as hydrochloride: 30 mg, 60 mg, 180 mg |
||||||||||||||||||||||
loratadine (Claritin):
|
||||||||||||||||||||||
|
Mechanism of Action Long-acting tricyclic antihistamine with selective peripheral histamine H1-receptor antagonistic properties Dosage Oral: Seasonal allergic rhinitis, chronic idiopathic urticaria: Children 2-5 years: 5 mg once daily Children >/= 6 years and Adults: 10 mg once daily Elderly: Peak plasma levels are increased; elimination half-life is slightly increased; specific dosing adjustments are not available Dosage adjustment in renal impairment: Clcr </= 30 mL/minute: Children 2-5 years: 5 mg every other day Children >/= 6 years and Adults: 10 mg every other day Supplied Syrup (Claritin®): 1 mg/mL (120 mL) [contains sodium benzoate; fruit flavor] Tablet (Alavert™, Claritin®, Claritin® Hives Relief; Tavist® ND): 10 mg Tablet, rapidly-disintegrating: 10 mg Alavert™: 10 mg [contains phenylalanine 8.4 mg/tablet] Claritin® RediTabs®: 10 mg [mint flavor] Dimetapp® Children's ND: 10 mg [contains phenylalanine 8.4 mg/tablet] |
||||||||||||||||||||||
Combination decongestant/antihistamine (Formulary) |
||||||||||||||||||||||
Actifed (triprolidine 2.5mg + psuedoephedrine
60mg):
|
||||||||||||||||||||||
|
Dosing (Adult): 1 tablet orally every 4 to 6 hours as needed.
Maximum of 4 tablets/day. | ||||||||||||||||||||||
Allegra D
|
||||||||||||||||||||||
|
(pseudoephedrine 120mg + fexofenadine 60mg). Dosing:: one tablet twice daily for adults and children 12 years of age and older (should be taken on an empty stomach). A dose of one tablet once daily is recommended as the starting dose in patients with decreased renal function. |
||||||||||||||||||||||
Claritin-D
|
||||||||||||||||||||||
|
Claritin-D 24 hour (10mg loratadine + 240mg psuedophedrine) Dosing (Adult): one tablet po qd. Claritin-D 24 Hour Extended Release Tablets should generally be avoided in patients with hepatic insufficiency. Patients with renal insufficiency (GFR <30 L/min) should be given a lower initial dose (one tablet every other day) because they have reduced clearance of loratadine and pseudoephedrine. Patients who have a history of difficulty in swallowing tablets or who have known upper gastrointestinal narrowing or abnormal esophageal peristalsis should not use this product. |
||||||||||||||||||||||
Other antihistamines (Sedating) |
||||||||||||||||||||||
chlorpheniramine (Chlor-Trimeton)
|
||||||||||||||||||||||
|
Adult (usual): 4 mg po every 4 to 6 hrs; maximum dose:
24 mg/day. Sustained-release: 8 or 12 mg po every 8 to 12 hours. Maximum
dose: 24 mg/day. Supplied: Extended Release Cap: 6 mg, 8 mg, 12 mg Liquid/syrup: 2 mg/5 ml Tablet: 2 mg, 4 mg. Chewable: 2 mg EExtended Release tab: 8 mg, 12 mg, 16 mg |
||||||||||||||||||||||
clemastine (Tavist)
|
||||||||||||||||||||||
|
Tavist 12 Hour Allergy Tablets: Clemastine fumarate, USP 1.34 mg
(equivalent to 1 mg clemastine). Adults and children 12 years of age and older: take 1 tablet every 12 hours, not more than 2 tablets in 24 hours unless directed by a doctor. |
||||||||||||||||||||||
cyproheptadine (Periactin):
|
||||||||||||||||||||||
|
Mechanism of Action A potent antihistamine and serotonin antagonist, competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract Dosage - Oral: Children: Allergic conditions: 0.25 mg/kg/day or 8 mg/m 2 /day in 2-3 divided doses or 2-6 years: 2 mg every 8-12 hours (not to exceed 12 mg/day) 7-14 years: 4 mg every 8-12 hours (not to exceed 16 mg/day) Migraine headaches: 4 mg 2-3 times/day Children >/= 12 years and Adults: Spasticity associated with spinal cord damage: 4 mg at bedtime; increase by a 4 mg dose every 3-4 days; average daily dose: 16 mg in divided doses; not to exceed 36 mg/day Children >13 years and Adults: Appetite stimulation (anorexia nervosa): 2 mg 4 times/day; may be increased gradually over a 3-week period to 8 mg 4 times/day Adults: Allergic conditions: 4-20 mg/day divided every 8 hours (not to exceed 0.5 mg/kg/day) Cluster headaches: 4 mg 4 times/day Migraine headaches: 4-8 mg 3 times/day Supplied Syrup, as hydrochloride: 2 mg/5 mL (473 mL) [contains alcohol 5%; mint flavor] Tablet, as hydrochloride: 4 mg |
||||||||||||||||||||||
dimenhydrinate (Dramamine):
|
||||||||||||||||||||||
|
Mechanism of Action Competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract; blocks chemoreceptor trigger zone, diminishes vestibular stimulation, and depresses labyrinthine function through its central anticholinergic activity Dosage - Oral: Children: 2-5 years: 12.5-25 mg every 6-8 hours, maximum: 75 mg/day 6-12 years: 25-50 mg every 6-8 hours, maximum: 150 mg/day Adults: 50-100 mg every 4-6 hours, not to exceed 400 mg/day Supplied Caplet (TripTone®): 50 mg Tablet (Dramamine®): 50 mg Tablet, chewable (Dramamine®): 50 mg [contains phenylalanine 1.5 mg/tablet and tartrazine; orange flavor] |
||||||||||||||||||||||
diphenhydramine (Benadryl):
|
||||||||||||||||||||||
|
Mechanism of Action Competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract; anticholinergic and sedative effects are also seen Dosing- Children: Oral, I.M., I.V.: Treatment of moderate to severe allergic reactions: 5 mg/kg/day or 150 mg/m 2 /day in divided doses every 6-8 hours, not to exceed 300 mg/day Minor allergic rhinitis or motion sickness: 2 to <6 years: 6.25 mg every 4-6 hours; maximum: 37.5 mg/day 6 to <12 years: 12.5-25 mg every 4-6 hours; maximum: 150 mg/day >/= 12 years: 25-50 mg every 4-6 hours; maximum: 300 mg/day Night-time sleep aid: 30 minutes before bedtime: 2 to <12 years: 1 mg/kg/dose; maximum: 50 mg/dose >/= 12 years: 50 mg Oral: Antitussive: 2 to <6 years: 6.25 mg every 4 hours; maximum 37.5 mg/day 6 to <12 years: 12.5 mg every 4 hours; maximum 75 mg/day >/= 12 years: 25 mg every 4 hours; maximum 150 mg/day I.M., I.V.: Treatment of dystonic reactions: 0.5-1 mg/kg/dose Adults: Oral: 25-50 mg every 6-8 hours Minor allergic rhinitis or motion sickness: 25-50 mg every 4-6 hours; maximum: 300 mg/day Moderate to severe allergic reactions: 25-50 mg every 4 hours, not to exceed 400 mg/day Nighttime sleep aid: 50 mg at bedtime I.M., I.V.: 10-50 mg in a single dose every 2-4 hours, not to exceed 400 mg/day Dystonic reaction: 50 mg in a single dose; may repeat in 20-30 minutes if necessary Topical: For external application, not longer than 7 days Supplied Elixir, as hydrochloride: 12.5 mg/5 mL (480 mL) Caplet, as hydrochloride: 25 mg, 50 mg Capsule, as hydrochloride: 25 mg, 50 mg Injection, solution, as hydrochloride: 50 mg/mL (1 mL) Solution, topical, as hydrochloride [spray] (Benadryl® Itch Stopping Extra Strength): 2% (60 mL) [contains zinc acetate 0.1%] Tablet, chewable, as hydrochloride (Benadryl® Children's Allergy): 12.5 mg [contains phenylalanine 4.2 mg/tablet; grape flavor] Tablet, orally-disintegrating, as citrate (Benadryl® Children's Allergy Fastmelt®): 19 mg [equivalent to diphenhydramine hydrochloride 12.5 mg; contains phenylalanine 4.5 mg/tablet and soy protein isolate; cherry flavor] |
||||||||||||||||||||||
hydroxyzine (Atarax, Vistaril):
|
||||||||||||||||||||||
|
Adult (usual): Antiemetic: I.M.: 25-100 mg/dose every 4-6 hours as needed. Anxiety: Oral: 25-100 mg 4 times/day; maximum: 600 mg/day. Preoperative sedation: Oral: 50-100 mg. I.M.: 25-100 mg. Management of pruritus: Oral: 25 mg 3-4 times/day Administration For I.M. administration in children, injections should be made into the midlateral muscles of the thigh; SubQ, intra-arterial, and I.V. administration not recommended since thrombosis and digital gangrene can occur |
||||||||||||||||||||||
promethazine (Phenergan)
|
||||||||||||||||||||||
|
Adult (usual) Allergy: 25 mg orally at bedtime or 12.5 mg orally before meals and at bedtime. Allergy: 25 mg IV or IM, may repeat within 2 hrs if needed. Anesthesia adjunct: 25-50 mg IM or IV prior to surgery. Motion sickness: 25 mg orally twice daily. Nausea and vomiting: 12.5-25 mg orally ,rectally, IV or IM every 4 to 6 hrs. Sedation: 25-50 mg orally or 50 mg rectally. Administration Formulations available for oral, rectal, I.M./I.V. administration; not for SubQ or intra-arterial administration. Administer I.M. into deep muscle (preferred route of administration). Due to the possibility of orthostatic hypotension, I.V. administration is not the preferred route. Solution for injection may be diluted in 25-100 mL NS or D5W (maximum concentration of 25 mg/mL) and infused over 15-30 minutes at a rate </= 25 mg/minute. [Supplied: 25, 50 mg/ml Injection. 12.5, 25, 50mg suppository. 10 mg/5 ml Syrup. 10, 25 , 50mg Tablet] |
||||||||||||||||||||||
Disclaimer |
||||||||||||||||||||||
|
Listed dosages are for - Adult patients ONLY. PLEASE READ THE
DISCLAIMER CAREFULLY BEFORE
ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE
TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.
GlobalRPH does not directly or indirectly practice medicine or provide
medical services and therefore assumes no liability whatsoever of any
kind for the information and data accessed through the Service or for
any diagnosis or treatment made in reliance thereon. David F. McAuley, Pharm.D., R.Ph. GlobalRPh Inc. |
||||||||||||||||||||||
| Disclaimer Contact Us Privacy Policy Website Search | We comply with the HONcode standard for health trustworthy information: Verify here. Copyright © 2007 GlobalRPh Inc. |
![]() |
|
